Plus: How AI can make it easier to find drugs from nature and a study suggests Ozempic could treat alcoholism.

Insilico Medicine(“Insilico”), a global leading generative artificial intelligence (AI)-driven biotechnology company, will be hosting Pharma.AI Week featuring in-depth webinar series from November ...

Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

Insilico Medicine plans to push its computer-designed drug into pivotal clinical trials after a phase 2a study demonstrated ...

The global artificial intelligence (AI) in drug discovery market is projected to reach USD 6.89 billion by 2029 from USD 1.86 ...

Columnist Sam Kirton encourages the IPF community to get a jump on legislative advocacy before the new congressional term begins.

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

This announcement has been reviewed by Dr. Gábor Bada, Falcon Oil & Gas Ltd's Technical Advisor. Dr. Bada obtained his ...

at 09:00 Insilico Medicine Announces Positive Topline Results of ISM001-055 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF) Developed Using Generative AI Insilico Medicine ("Insilico"), a ...